| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Alcon Research |
| Information provided by: | Alcon Research |
| ClinicalTrials.gov Identifier: | NCT00065728 |
Purpose
This is a 24 month study of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
| Condition | Intervention | Phase |
|
Macular Degeneration |
Drug: Anecortave Acetate |
Phase III |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Macular Degeneration |
| ChemIDplus related topics: | Anecortave acetate |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients With Subfoveal Exudative Age-Related Macular Degeneration (AMD) |
| Estimated Enrollment: | 150 |
| Study Start Date: | May 2003 |
Patients will receive posterior juxtascleral injections of 15 mg Anecortave Acetate Sterile Suspension at 6-month intervals during the 24-month study. The patients will receive periodic visual acuity evaluations during the study.
Eligibility
| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients with subfoveal exudative age-related macular degeneration (AMD) who were previously enrolled in long-term studies with anecortave acetate.
Contacts and Locations| Contact: Alcon Clinical | 817-568-6747 | intldev@alconlabs.com |
| United States, Texas | |||||
| Belgium,France,Germany,Hungary,Italy,Netherlands,Poland,Spain,Sweden,UK | Recruiting | ||||
| Central Contact Ft. Worth, Texas, United States, 76134 | |||||
| Alcon Research |
| Study Director: | Terry Wiernas, PhD | Alcon Research |
More Information
Click here for more information about this study: A Phase III Clinical Trial for AMD: Information for Potential Participants
|
| Study ID Numbers: | C-03-15 |
| First Received: | July 31, 2003 |
| Last Updated: | July 13, 2007 |
| ClinicalTrials.gov Identifier: | NCT00065728 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
